CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies

Crispr Therapeutics AG ( (CRSP) ) just unveiled an update.

On January 12, 2026, CRISPR Therapeutics issued an update on its pipeline, underscoring progress across in vivo gene editing, cell therapy and regenerative medicine programs. In 2025, the company reported positive Phase 1 data for CTX310, showing deep and durable reductions in triglycerides and LDL cholesterol after a single IV dose with a favorable safety profile, and has moved the ANGPTL3-targeting therapy into Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia. CTX320, targeting LPA, has yielded up to 73% reductions in the dose-escalation phase, while next-generation LPA candidate CTX321, designed with a more potent guide RNA and the same LNP platform, is in IND/CTA-enabling studies alongside CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency, reflecting a broadening cardiovascular and metabolic portfolio. The company also highlighted progress for its CAR-T candidate zugocabtagene geleucel (zugo-cel) in autoimmune diseases and B-cell malignancies, with early systemic lupus erythematosus data showing sustained drug-free clinical remission and B-cell depletion in heavily pretreated patients, and an expanded oncology strategy via a collaboration with Eli Lilly to test zugo-cel with pirtobrutinib in aggressive B-cell lymphomas. In regenerative medicine, CRISPR Therapeutics reported promising 12‑month C-peptide data from diabetes candidate CTX211 that are guiding a shift toward next-generation hypoimmune cell therapy CTX213, which has shown strong preclinical efficacy and is being advanced toward clinical testing, signaling the company’s intent to consolidate its position as a leading player in gene-edited therapies across multiple high-need disease areas.

The most recent analyst rating on (CRSP) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Spark’s Take on CRSP Stock

According to Spark, TipRanks’ AI Analyst, CRSP is a Underperform.

Crispr Therapeutics AG’s overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. Technical analysis further indicates bearish momentum, while valuation metrics highlight the company’s current financial struggles. The absence of earnings call and corporate events data limits additional insights.

To see Spark’s full report on CRSP stock, click here.

More about Crispr Therapeutics AG

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-editing therapies across cardiovascular, autoimmune, immuno-oncology and regenerative medicine indications, leveraging its proprietary in vivo CRISPR-based platforms, including a lipid nanoparticle delivery system and hypoimmune cell engineering technologies, to address severe and refractory diseases such as hypertriglyceridemia, hypercholesterolemia, B‑cell malignancies, autoimmune disorders and diabetes.

Average Trading Volume: 2,127,778

Technical Sentiment Signal: Buy

Current Market Cap: $5.37B

For a thorough assessment of CRSP stock, go to TipRanks’ Stock Analysis page.